Amarin Corporation plc (NASDAQ: AMRN) announced that the 2026 American College of Cardiology/American Heart Association/Multisociety Dyslipidemia Guideline Update recommends icosapent ethyl for reducing cardiovascular risk in patients with elevated triglycerides who remain at risk despite statin therapy.

The updated guidelines recognize that patients achieving low-density lipoprotein cholesterol targets may still face cardiovascular events, particularly those with elevated triglyceride levels. The guidelines distinguish between therapies aimed at pancreatitis prevention and those proven to reduce atherosclerotic cardiovascular disease events.

The recommendations support adding evidence-based therapies like icosapent ethyl for patients who remain at elevated cardiovascular risk despite optimized statin therapy. The guidelines note that fenofibrates do not reduce cardiovascular risk when added to statin therapy, while icosapent ethyl has demonstrated cardiovascular event reduction in the REDUCE-IT trial.

Amarin's VASCEPA/VAZKEPA contains icosapent ethyl and is approved by the FDA as the first oral therapy proven to reduce cardiovascular events by 25% when added to statin therapy in high-risk patients with elevated triglycerides. The drug has been prescribed more than 30 million times globally.

The REDUCE-IT study followed 8,179 patients over seven years at more than 400 clinical sites in 11 countries. The trial evaluated the drug's effect in adult patients with controlled LDL cholesterol levels between 41-100 mg/dL and persistent elevated triglycerides between 135-499 mg/dL.

VASCEPA is approved in the United States for reducing cardiovascular events in specific patient populations and for reducing triglyceride levels in patients with severe hypertriglyceridemia. The drug is also approved and sold in multiple international markets under the brand name VAZKEPA in Europe.